- Details
- Ashish Kamat engages with Andrea Necchi about the use of next-generation sequencing (NGS) in urothelial carcinoma. Dr. Necchi highlights consensus recommendations from a recent retreat, emphasizing the importance of NGS in identifying actionable mutations across different stages of bladder cancer. He underscores the need for careful tissue management, recommending NGS especially when clinical tria...
|
- Details
- Sam Chang interviews Roger Li about the MoonRISe-1 trial. This phase 3 study explores the use of TAR-210, an innovative intravesical delivery system for the tyrosine kinase inhibitor erdafitinib, targeting patients with intermediate-risk non-muscle-invasive bladder cancer harboring FGFR alterations. Dr. Li explains that TAR-210, administered via a quick in-office procedure, continuously releases e...
|
- Details
- Zach Klaassen speaks with Brent Rose about advances in bladder-sparing therapies for localized bladder cancer. Dr. Rose highlights the surprising underutilization of chemo-radiation in bladder cancer treatment, despite its established role in other cancers and the significant risks and quality of life issues associated with cystectomy. He underscores the efficacy of chemo-radiation, drawing on dat...
|
- Details
- Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. Speaking with Dr. Sam Chang of Vanderbilt, Dr. Porten explains that TAR-200 releases gemcitabine directly into the bladder over a sustained period, offeri...
|
- Details
- José Daniel Subiela Henriquez presented findings from his multicenter study on BCG therapy for very high-risk non-muscle-invasive bladder cancer (NMIBC). Dr. Subiela's research evaluates the effectiveness of BCG in a group where the European Association of Urology (EAU) had recommended radical cystectomy due to high progression risks. His study, involving 640 patients over 13 years, suggests that...
|
- Details
- Yair Lotan discusses the STRATA trial, a multicenter study comparing the Cxbladder Triage test to traditional cystoscopy in patients with microhematuria. This trial explores whether a high negative predictive value biomarker test can safely reduce the number of unnecessary cystoscopies in low-risk patients. Microhematuria, a common condition affecting millions annually in the U.S., is frequently o...
|
- Details
- Zach Klaassen interviews Roger Li about the CORE-001 trial for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Li highlights the significant need for bladder-sparing therapies for patients who are too frail or unwilling to undergo radical cystectomy. The trial explores the combination of cretostimogene grenadenorepvec, an oncolytic immunotherapy, with pembrolizumab. This combination shows...
|
- Details
- Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...
|
- Details
- Sam Chang interviews Edward Messing about his research on using apalutamide for non-muscle invasive bladder cancer. Dr. Messing discusses a trial aiming to explore whether antiandrogens like apalutamide can prevent bladder cancer recurrence, given its higher prevalence in men. This molecular proof-of-principle study, sponsored by the National Cancer Institute, focuses on the role of androgen recep...
|
- Details
- Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...
|
